Literature DB >> 16498049

Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.

Gherardo Mazziotti1, Giovanni Amato, Francesca Sorvillo, Marco Piscopo, Maria Rosaria Rizzo, Eleonora Lalli, Lorenza Iride, Michele Cioffi, Anna Maria Molinari, Giuseppe Paolisso, Carlo Carella.   

Abstract

AIM: To evaluate serum osteoprotegerin (OPG) concentrations in relation to age-dependent changes in serum markers of bone metabolism and systemic inflammation.
METHODS: Two-hundred and eighty-three healthy subjects were evaluated for plasma estimated creatinine clearance (Cr-clearance), C-reactive protein (CRP), bone alkaline phosphatase, C-telopeptides of type-1 collagen (CrossLaps), nuclear factor-kappaB ligand (RANKL) and OPG concentrations.
RESULTS: In adult subjects (82 cases aged between 27 and 64 years) serum OPG concentrations were significantly and independently correlated with RANKL and Cr-clearance (R(2): 0.29), but not with CRP and biochemical markers of bone metabolism. In old subjects who were between 65 and 84 years of age (52 cases) serum OPG concentrations were significantly higher as compared with the adult subjects and correlated independently and significantly with serum RANKL, Cr-clearance and CrossLaps values (R(2): 0.63). The highest OPG values were found in the long-lived subjects (149 cases with ages between 85 and 110 years) who also showed increased serum CrossLaps and CRP concentrations as compared with the younger subjects. However, in the long-lived subjects serum OPG concentrations were significantly and independently correlated with Cr-clearance and CRP (R(2): 0.45) but not with CrossLaps values.
CONCLUSIONS: These data would suggest that different factors might be responsible for the age-dependent enhancement of OPG production. Bone metabolism would seem to be the most important factor influencing serum OPG concentrations in old subjects under 85 years of age, whereas in long-lived subjects the circulating values of this cytokine seem to be mainly correlated with serum CRP which could be a marker of inflammation and cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498049     DOI: 10.1530/eje.1.02099

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.

Authors:  J Coulson; L Bagley; Y Barnouin; S Bradburn; G Butler-Browne; H Gapeyeva; J-Y Hogrel; T Maden-Wilkinson; A B Maier; C Meskers; C Murgatroyd; M Narici; M Pääsuke; L Sassano; S Sipilä; N Al-Shanti; L Stenroth; D A Jones; J S McPhee
Journal:  Osteoporos Int       Date:  2017-06-05       Impact factor: 4.507

Review 2.  Calcium metabolism and vitamin D in the extreme longevity.

Authors:  Giovanni Passeri; Rosanna Vescovini; Paolo Sansoni; Carlo Galli; Claudio Franceschi; Mario Passeri
Journal:  Exp Gerontol       Date:  2007-07-04       Impact factor: 4.032

Review 3.  Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.

Authors:  Anne-Priscille Trouvin; Vincent Goëb
Journal:  Clin Interv Aging       Date:  2010-11-19       Impact factor: 4.458

4.  Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.

Authors:  Eva Kulcsar-Jakab; Zsofia Petho; Zoltan Pap; Edit Kalina; Roza Foldesi; Adam Balogh; Peter Antal-Szalmas; Harjit Pal Bhattoa
Journal:  BMC Musculoskelet Disord       Date:  2015-08-28       Impact factor: 2.362

5.  Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study.

Authors:  Dario Bruno; Anna Laura Fedele; Barbara Tolusso; Angelina Barini; Luca Petricca; Clara Di Mario; Antonella Barini; Luisa Mirone; Gianfranco Ferraccioli; Stefano Alivernini; Elisa Gremese
Journal:  Front Med (Lausanne)       Date:  2021-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.